e-NIOS
e-NIOS is a Greek bioinformatics company developing BioInfoMiner, an AI-powered multi-omic interpretation platform that grounds AI models to biological mechanisms for pharmaceutical researchers, biotech firms, and precision medicine applications.
- Company typePrivate
- Founded2014
- HeadquartersKallithéa, Greece
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What e-NIOS does
e-NIOS (legal entity ENIOS APPLICATIONS PC) is a Greek bioinformatics company that develops BioInfoMiner, an AI-powered multi-omic interpretation platform designed to translate high-throughput molecular data into mechanistically explainable biological insights. Founded in 2014 and headquartered in Kallithea, Athens, the company targets the interpretation bottleneck pharmaceutical and biotechnology companies face when moving from raw omic data to actionable drug targets, with secondary reach into academic and precision medicine research. The company is small, with 1-10 employees per firmographic data.
The BioInfoMiner platform applies a proprietary semantic processing algorithm to transform raw biological annotation terms from curated ontologies (Gene Ontology, Human Phenotype Ontology, Mammalian Phenotype Ontology, REACTOME pathways) into noise-free knowledge networks. Graph-theoretic prioritization then identifies structurally central biological processes, correcting for annotation bias where heavily studied genes dominate results, and ranks driver or linker genes between prioritized processes to produce compact molecular signatures. The platform unifies interpretation across transcriptomics, genomics, epigenomics, and proteomics in a single auditable pipeline, and has been validated in 50+ peer-reviewed publications in journals including Nature Communications, Cell Metabolism, EMBO Molecular Medicine, J Cell Biol, Bioinformatics, and Scientific Reports.
e-NIOS operates a hybrid revenue model with three streams: BioInfoMiner platform licensing (subscription-style recurring access on a quote-based, undisclosed price structure), collaborative research partnerships delivered as professional services, and public research grants from European and national programmes including Horizon Europe, EPAnEK, Marie Skłodowska-Curie actions, and Erasmus+. Distribution runs through direct enterprise sales to pharmaceutical and biotech firms, plus an OEM channel via a 2018 strategic integration with the Seven Bridges biomedical data platform. Pricing is not publicly disclosed; the company's website explicitly invites licensing inquiries and research collaborations.
e-NIOS firmographics
Firmographics- Name
- e-NIOS
- Legal name
- ENIOS APPLICATIONS PC
- Website
- https://e-nios.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- e-NIOS is a Greek bioinformatics company developing BioInfoMiner, an AI-powered multi-omic interpretation platform that grounds AI models to biological mechanisms for pharmaceutical researchers, biotech firms, and precision medicine applications.
- Ownership category
- akta.pro rank
e-NIOS industry classification
Industry- Product category
- Bioinformatics Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
- akta.pro secondary industries
- Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF)
Keywords
Where e-NIOS is headquartered
LocationHeadquarters
- HQ city
- Kallithéa
- HQ country
- Greece
- HQ region
- Europe
Offices1 record
Markets served
e-NIOS business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- BioInfoMiner Platform Licensing: License-based access to the BioInfoMiner platform for multi-omic data interpretation. The company mentions being open for licensing inquiries.
- Research Partnerships: Collaborative research partnerships with academic institutions and pharmaceutical companies, contributing bioinformatics analysis services using the BioInfoMiner platform.
- Public Research Grants: Funding from European and national research programmes including Horizon Europe, EPAnEK, Marie Skłodowska-Curie actions, and Erasmus+ initiatives.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
e-NIOS product offering
Product offeringCore offering
e-NIOS provides BioInfoMiner, a software platform that performs unsupervised, explainable AI-assisted interpretation of multi-omic data (transcriptomics, genomics, epigenomics, proteomics). The platform grounds AI predictions to biological mechanisms through semantic network construction, delivering prioritized biomarker signatures, driver gene identification, and pathway analysis to pharmaceutical, biotech, and academic research customers via licensing and collaborative research partnerships.
Product overview
e-NIOS offers a single unified platform called BioInfoMiner, which is a next-generation omic interpretation engine that performs automated, explainable AI-assisted multi-omic analysis. The platform integrates diverse omics data (transcriptomics, genomics, epigenomics, proteomics) through advanced semantic processing, delivering actionable biological insights from raw omic data to prioritized signatures and driver genes.
Differentiator
Problem solved
Functional benefit
Brands
- BioInfoMiner: Advanced interpretation engine that grounds AI models to mechanistic biology through sophisticated semantic processing, enabling rapid detection of causal genes and biological mechanisms with full transparency.
Products and services
- BioInfoMiner Platform AI-powered multi-omic interpretation platform that performs unsupervised, explainable analysis of transcriptomics, genomics, epigenomics, and proteomics data. Grounds AI models to biological mechanisms through advanced semantic processing, delivering prioritized biomarker signatures, driver gene identification, and pathway analysis for pharmaceutical, biotech, and academic research customers.
- Multi-Omic Interpretation Services Collaborative bioinformatics analysis services delivered through research partnerships with academic institutions and pharmaceutical companies, applying BioInfoMiner to interpret customer-supplied multi-omic datasets, identify mechanisms of action, and produce molecular biomarkers (e.g., TheraSyn RNAseq analysis for Parkinson's disease antisense therapy).
Quantifiable outcome
- Over 90% of drug candidates fail in clinical trials, with significant failures attributed to flawed target selection from pre-clinical omic data interpretation - e-NIOS addresses this critical bottleneck
Companies that use e-NIOS
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
e-NIOS technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature6 records
e-NIOS partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- Seven BridgescoreStrategic partnership announced in September 2018 to break the biomarker bottleneck. BioInfoMiner was integrated into the Seven Bridges biomedical data platform for data-driven discovery of biomarker signatures. This integration enabled Seven Bridges users to access e-NIOS's advanced multi-omic interpretation capabilities.
- CHIRON Project (Horizon Europe, Grant No. 101130240)coreMSCA-SE project funded by the European Commission focused on understanding how tumours evade the immune system. e-NIOS contributes advanced in silico modelling tools based on AI and Machine Learning to modulate non-canonical death receptor signalling, making tumours sensitive to cell death again.
- DISCOVER Network (Marie Skłodowska-Curie / Horizon 2020)minorMarie Skłodowska-Curie and Horizon 2020 project bringing together researchers in cell death signalling, immunology, protein structural chemistry, drug design, bioinformatics and computational biology. e-NIOS contributes bioinformatics expertise to this cross-sectoral network.
- INSPIRED Network (IRE1 Biology & Drug Discovery)minorNetwork of academic and industry researchers in IRE1 biology and drug discovery. e-NIOS shares knowledge and expertise to develop new treatments for cancer and neurodegenerative diseases.
- TRAIN-ERS Network (Endoplasmic Reticulum Stress Research)minorEndoplasmic Reticulum stress research network bringing researchers together with world-leading academics, clinicians and industry personnel. e-NIOS participates in advancing understanding of ER Stress Response and innovative treatment strategies.
- INNOCENT NetworkminorInternational research and innovation network where e-NIOS participates as a computational biology and bioinformatics partner, contributing expertise in multi-omic data interpretation to support network-wide research objectives including breast cancer nano-pharmaceuticals development.
- BioS Project (Erasmus+ / Sector Skills Alliances)minorErasmus+ Sector Skills Alliance project 'Digital Skills on Computational Biology' aimed at advancing digital skills of medical doctors through new modular vocational curricula on Computational Biology & Bioinformatics.
- TheraSyn Project (T2EDK-01291)coreNationally funded collaborative research project developing next generation anti-sense molecules for Parkinson's disease therapy. e-NIOS performed comprehensive bioinformatics analysis of RNAseq data using BioInfoMiner, helping assess mechanisms of action and identify molecular biomarkers.
- BIOFOS Project (T2EDK-03126)minorEU co-funded project (EPAnEK 2014-2020) applying metagenomics and bioinformatics technologies for identification of microorganisms affecting stone surfaces of monuments and development of nano-biomaterials for cultural heritage protection.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
e-NIOS competitors and assessment
Company assessmentDirect peers
- Seven Bridges (Velsera): Biomedical data analysis platform serving pharma and research institutions. e-NIOS already has a strategic partnership with Seven Bridges integrating BioInfoMiner, making them both a distribution channel and a potential competitive platform if Seven Bridges builds native interpretation capabilities.
- DNAnexus: Cloud-based genomics and biomedical data platform serving pharma R&D and clinical diagnostics. Competes directly for enterprise pharma bioinformatics budgets and offers integrated multi-omic analysis capabilities similar to BioInfoMiner's positioning.
- Genedata: Enterprise bioinformatics software for pharma R&D, with established penetration in top-20 pharma. Provides similar multi-omic data interpretation capabilities and competes for the same pharmaceutical enterprise licensing budgets as BioInfoMiner.
- SOPHiA Genetics: AI-powered genomics platform for clinical and research applications, with public-company scale and global footprint. Competes in the same AI-driven multi-omic interpretation category targeting hospitals and pharma.
- Rosalind (formerly OnRamp Bioinformatics): Cloud-based bioinformatics platform for multi-omic data analysis with emphasis on biologist-friendly interpretation. Targets similar pharma and academic customers and offers competing explainable analysis capabilities.
- Partek (now part of Illumina): Bioinformatics software suite for genomic and multi-omic data analysis, now backed by Illumina's sequencing market dominance. Offers similar transcriptomics and genomics interpretation workflows to BioInfoMiner with broader commercial reach.
Broad incumbents
- Illumina: Dominant sequencing and genomics platform with expanding bioinformatics portfolio including Partek and DRAGEN. Represents a broad incumbent that could bundle competing interpretation capabilities with sequencing instruments to squeeze independent platforms like BioInfoMiner.
- Qiagen Digital Insights: Bioinformatics business unit of Qiagen providing genomic and clinical interpretation software. Serves similar pharma and clinical customers with a broader portfolio that includes sample technologies, competing for the same interpretation spend.
- Schrödinger: Computational chemistry and molecular simulation platform with expanding biology capabilities. Public company with resources to extend into multi-omic interpretation, potentially competing with BioInfoMiner in the target identification and biomarker discovery workflows.
Emerging players
- BC Platforms: Genomics and real-world data platform focused on precision medicine partnerships with pharma. Smaller-scale emerging player in the same bioinformatics-for-precision-medicine category as e-NIOS, with comparable go-to-market through pharma collaborations.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
e-NIOS social profiles
Digital presencee-NIOS financial estimates
Financial estimateRevenue estimate
Valuation estimate
e-NIOS leadership team
Management profileNumber of profiles
Profiles2 records
e-NIOS funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
e-NIOS M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about e-NIOS
What does e-NIOS do?
e-NIOS provides BioInfoMiner, a software platform that performs unsupervised, explainable AI-assisted interpretation of multi-omic data (transcriptomics, genomics, epigenomics, proteomics). The platform grounds AI predictions to biological mechanisms through semantic network construction, delivering prioritized biomarker signatures, driver gene identification, and pathway analysis to pharmaceutical, biotech, and academic research customers via licensing and collaborative research partnerships.
Is e-NIOS a public or private company?
e-NIOS is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was e-NIOS founded?
e-NIOS was founded in 2014. It employs 1 to 10 people.
Where is e-NIOS based?
e-NIOS is headquartered in Kallithéa, Greece, in the Europe region.
How does e-NIOS make money?
Three revenue lines are on record. BioInfoMiner Platform Licensing is the primary driver. The others are research Partnerships and public Research Grants.
Who are e-NIOS's main competitors?
Direct peers on record are Seven Bridges (Velsera), DNAnexus, Genedata, SOPHiA Genetics, Rosalind (formerly OnRamp Bioinformatics) and Partek (now part of Illumina). Broad incumbents are Illumina, Qiagen Digital Insights and Schrödinger. BC Platforms is listed as an emerging player.
Does e-NIOS have an API?
No public API is recorded for e-NIOS.
What industry is e-NIOS in?
e-NIOS's product category is Bioinformatics Software. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services. Its NAICS code is 541714 and its SIC code is 2835.